Nuvectis Pharma
NVCT · Nasdaq · United States
Share price · NVCT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NVCT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+17.7%
Nothing announced by NVCT that day or the session before.
- 4 Nov 2026-4.5%
- 26 Oct 2026-7.8%
- 30 Jun 2026-35.5%
- 24 Jun 2026+39.5%
- 22 Jun 2026+19.6%
Nothing announced by NVCT that day or the session before.
- 18 Jun 2026+9.8%
Nothing announced by NVCT that day or the session before.
- 16 Jun 2026+7.1%
Nothing announced by NVCT that day or the session before.
- 15 May 2026-11.3%
Nothing announced by NVCT that day or the session before.
- 13 May 2026+10.5%
Nothing announced by NVCT that day or the session before.
Share of unusual movement by asset
For each asset, the share of NVCT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 25% |
| Sessions with no dated event | — | 75% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | SRC and YES1 (Src-family kinases)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $27M | $141M | $30M-$25M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $4.7M | $22M | $7.0M-$4.5M operating cash flow | report ↗ |
| 2026-Q1 | — | $4.1M | $25M | $6.0M-$6.5M operating cash flow | report ↗ |
| 2025-Q3 | — | $5.8M | $35M | $7.5M-$4.5M operating cash flow | report ↗ |
| 2025-Q2 | — | $3.6M | $27M | $6.3M-$3.4M operating cash flow | report ↗ |
| 2025-Q1 | — | $3.7M | $30M | $5.3M-$4.2M operating cash flow | report ↗ |
| 2024-Q3 | — | $2.8M | $17M | $4.2M-$2.4M operating cash flow | report ↗ |
| 2024-Q2 | — | $2.9M | $18M | $4.4M-$3.0M operating cash flow | report ↗ |
| 2024-Q1 | — | $2.7M | $19M | $4.2M-$4.4M operating cash flow | report ↗ |
| 2023-Q3 | — | $4.5M | $22M | $5.9M-$3.2M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.3M | $25M | $5.7M-$4.1M operating cash flow | report ↗ |
| 2023-Q1 | — | $2.4M | $15M | $4.0M-$4.8M operating cash flow | report ↗ |
| 2022-Q3 | — | $4.5M | $24M | $5.9M-$4.4M operating cash flow | report ↗ |
| 2022-Q2 | — | $2.5M | $14M | $3.6M-$2.5M operating cash flow | report ↗ |
| 2022-Q1 | — | $1.8M | $17M | $2.9M-$3.1M operating cash flow | report ↗ |
| 2021-Q3 | — | $4.2M | $6.8M | $4.7M-$4.4M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $18M | $32M | $26M | report ↗ |
For fiscal 2025, Nuvectis Pharma reported revenue of $0M (prior year $0M), R&D spend of $18.2M, up 41.1% YoY, and cash and cash equivalents of $31.6M at year-end. The company reported a net loss of $26.4M for the year, compared with $19.0M in 2024, with the increase including $6.0M in non-cash stock-based compensation and $2.4M in one-time milestone license fees.
Nuvectis is advancing NXP900, an oral small-molecule SFK inhibitor that has completed Phase 1a dose escalation; the Phase 1b monotherapy study and a Phase 1b combination with osimertinib in EGFR-mutated non-small cell lung cancer are enrolling, and a combination with lorlatinib in ALK-positive NSCLC is pending commencement. Management expects multiple potential NXP900 Phase 1b data readouts in 2026 and states that current cash is expected to support operations through multiple potential Phase 1b milestones and well into the second half of 2027.
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($1.2M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-03 | Carson Michael J. · Vice President, Finance | Award / grant | 30,000 | — | — | Form 4 |
| 2026-06-30 | BENTSUR RON · director, Chairman & CEO, 10% owner | Open-market purchase | 12,500 | $20.00 | $250K | Form 4 |
| 2026-06-30 | Mosseri Marlio Charles · 10% owner | Open-market purchase | 50,000 | $18.32 | $916K | Form 4 |
| 2026-06-11 | Kaplan Matthew L. · director | Award / grant | 35,000 | — | — | Form 4 |
| 2026-06-11 | Sanchez Juan · director | Award / grant | 35,000 | — | — | Form 4 |
| 2026-06-11 | Oliviero James F III · director | Award / grant | 35,000 | — | — | Form 4 |
| 2026-06-11 | Hoberman Kenneth · director | Award / grant | 35,000 | — | — | Form 4 |
| 2026-01-06 | Carson Michael J. · Vice President, Finance | Award / grant | 61,200 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 61 reporting institutions held 4.4M shares ($34.2M, 12.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 764,441 | $5.9M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 659,879 | $5.1M |
| 3 | IRIDIAN ASSET MANAGEMENT LLC/CT | 651,757 | $5.0M |
| 4 | Occam Crest Management LP | 407,147 | $3.1M |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 384,105 | $3.0M |
| 6 | BALDWIN WEALTH PARTNERS LLC/MA | 378,625 | $2.9M |
| 7 | STATE STREET CORP | 166,516 | $1.3M |
| 8 | NORTHERN TRUST CORP | 124,212 | $960K |
| 9 | VANGUARD FIDUCIARY TRUST CO | 114,842 | $888K |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 105,286 | $814K |
| 11 | VANGUARD PORTFOLIO MANAGEMENT LLC | 92,154 | $712K |
| 12 | CITADEL ADVISORS LLC | 78,425 | $606K |
| 13 | OPPENHEIMER & CO INC | 73,566 | $569K |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 49,645 | $384K |
| 15 | GOLDMAN SACHS GROUP INC | 41,124 | $318K |